Salomón Salazar-Londoño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salomón Salazar-Londoño has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Germán Borda
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital , Stavanger
6 shared publications - Dag Aarsland
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway
4 shared publications - Jonathan Patricio Baldera
Stavanger University Hospital, Stavanger Norway
3 shared publications - Agustín Ibáñez
Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago de Chile, Chile
2 shared publications - Anna Zettergren
Neuropsychiatric Epidemiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal Sweden
2 shared publications - Carlos Alberto Cano-Gutiérrez
Pontificia Universidad Javeriana
2 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (4) , e70443
Contextualizing Blood‐Based Biomarkers for Dementia Globally
Blood‐based biomarkers (BBMs) are transforming the diagnostic landscape of Alzheimer's disease by enabling scalable, less invasive, and potentially earlier biological characterization. However, most evidence supporting their performance, interpretation, and clinical integration derives from highly selected cohorts in high‐income settings, raising concerns about external validity, threshold transportability, and equitable implementation across diverse populations. In this Opinion, we argue that advancing BBMs from analytical validity to real‐world use requires a shift from biomarker‐centric accuracy toward context‐aware interpretation frameworks that explicitly account for social, environmental, and health system determinants. Using the amyloid, tau, and neurodegeneration (AT(N)) system as a conceptual anchor, we discuss how BBMs should be positioned according to clearly defined contexts of use, including triage, diagnostic support, prognosis, and clinical trial readiness, rather than treated as universal diagnostic substitutes. We examine how social determinants of health, life‐course exposures, and the cumulative exposome interact with comorbidity burden, systemic physiological stress, and health system readiness to shape biomarker distributions, trajectories, and clinical meaning. Evidence from Latin America and other underrepresented settings illustrates how cardiometabolic, vascular, and inflammatory load can modify baseline biomarker levels, challenging the uncritical transfer of cutoffs, reference ranges, and predictive models developed in high‐income settings. We conclude that BBMs hold substantial potential to expand access to biological characterization of Alzheimer's disease, but their responsible adoption depends on aligning biological signals with clinical context, social and environmental conditions, and system capacity. Without this alignment, large‐scale deployment risks misclassification, inequitable access to care, biased trial enrollment, and distorted estimates of disease burden. image
- 20 April 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (4) , e70443
Open AccessContextualizing Blood‐Based Biomarkers for Dementia Globally
Blood‐based biomarkers (BBMs) are transforming the diagnostic landscape of Alzheimer's disease by enabling scalable, less invasive, and potentially earlier biological characterization. However, most evidence supporting their performance, interpretation, and clinical integration derives from highly selected cohorts in high‐income settings, raising concerns about external validity, threshold transportability, and equitable implementation across diverse populations. In this Opinion, we argue that advancing BBMs from analytical validity to real‐world use requires a shift from biomarker‐centric accuracy toward context‐aware interpretation frameworks that explicitly account for social, environmental, and health system determinants. Using the amyloid, tau, and neurodegeneration (AT(N)) system as a conceptual anchor, we discuss how BBMs should be positioned according to clearly defined contexts of use, including triage, diagnostic support, prognosis, and clinical trial readiness, rather than treated as universal diagnostic substitutes. We examine how social determinants of health, life‐course exposures, and the cumulative exposome interact with comorbidity burden, systemic physiological stress, and health system readiness to shape biomarker distributions, trajectories, and clinical meaning. Evidence from Latin America and other underrepresented settings illustrates how cardiometabolic, vascular, and inflammatory load can modify baseline biomarker levels, challenging the uncritical transfer of cutoffs, reference ranges, and predictive models developed in high‐income settings. We conclude that BBMs hold substantial potential to expand access to biological characterization of Alzheimer's disease, but their responsible adoption depends on aligning biological signals with clinical context, social and environmental conditions, and system capacity. Without this alignment, large‐scale deployment risks misclassification, inequitable access to care, biased trial enrollment, and distorted estimates of disease burden. image
- Top Cited Papers
- 3 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1838-1851
The exposome of brain aging across 34 countries
The physical and social exposome affects human aging, and brain clocks may track its effects. However, most studies neglect multidomain exposures (physical, social and political) across diverse settings globally and their associations with brain aging. In this study, we characterized the associations between 73 country-level physical and social exposomal factors and multimodal brain age in 18,701 participants from 34 countries (healthy individuals and those with Alzheimer’s disease, frontotemporal lobar degeneration or mild cognitive impairment). Exposome effects were assessed using generalized additive models and meta-analytic frameworks. Aggregated exposome models explained up to 15.5-fold more variance than individual exposures (delta Akaike information criterion (ΔAIC): 2,034–3,127). Physical exposome was primarily associated with accelerated structural brain aging (limbic, subcortical and cerebellar regions), whereas social exposome was more strongly associated with functional brain aging (frontotemporal and limbic networks). Exposome burden accounted for 3.3−9.1-fold higher risk of accelerated aging, exceeding effects of clinical diagnoses. Findings were out-of-sample validated in cross-sectional and longitudinal designs, remained consistent across clinical subgroups and persisted after adjustment for demographics, age correction bias, cognition, scanner type and data quality. The exposome accelerates brain aging in health and disease, underscoring the need to address physical, social and political inequities.
- 3 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1838-1851
Top Cited PapersThe exposome of brain aging across 34 countries
The physical and social exposome affects human aging, and brain clocks may track its effects. However, most studies neglect multidomain exposures (physical, social and political) across diverse settings globally and their associations with brain aging. In this study, we characterized the associations between 73 country-level physical and social exposomal factors and multimodal brain age in 18,701 participants from 34 countries (healthy individuals and those with Alzheimer’s disease, frontotemporal lobar degeneration or mild cognitive impairment). Exposome effects were assessed using generalized additive models and meta-analytic frameworks. Aggregated exposome models explained up to 15.5-fold more variance than individual exposures (delta Akaike information criterion (ΔAIC): 2,034–3,127). Physical exposome was primarily associated with accelerated structural brain aging (limbic, subcortical and cerebellar regions), whereas social exposome was more strongly associated with functional brain aging (frontotemporal and limbic networks). Exposome burden accounted for 3.3−9.1-fold higher risk of accelerated aging, exceeding effects of clinical diagnoses. Findings were out-of-sample validated in cross-sectional and longitudinal designs, remained consistent across clinical subgroups and persisted after adjustment for demographics, age correction bias, cognition, scanner type and data quality. The exposome accelerates brain aging in health and disease, underscoring the need to address physical, social and political inequities.
- Open Access
- 8 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (2) , 442-451
Low Frequency of Dementia with Lewy Bodies Diagnosis in a Colombian Memory Clinic
Background: The global burden of dementia is increasing, particularly in low‐ and middle‐income countries. Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia but remains underreported and frequently misdiagnosed. Its prevalence in Latin America is largely unknown. Objective: The aim was to determine the frequency of DLB in a large memory clinic in Colombia and compare its clinical presentation with other neurodegenerative conditions, including Alzheimer's disease, frontotemporal dementia (FTD), vascular dementia, and Parkinson's disease dementia (PDD). Methods: We conducted a retrospective study at a referral memory clinic in Bogotá, Colombia, from January 2018 to December 2022. DLB was identified based on the Fourth Consensus Report criteria. Random samples of patients with other neurodegenerative conditions were selected for comparison, maintaining a maximum ratio of 4:1. Clinical assessments were conducted by an interdisciplinary team using validated neurocognitive, neuropsychiatric, neuropsychological, and functional tools. Imaging and biofluid biomarkers were not available. Results: Of 5518 patients, 38 (0.6%) were diagnosed with DLB. These individuals were predominantly male, with an average age of 72.3 years. Significant differences were observed between groups in age of onset, motor and cognitive function, and neuropsychiatric symptoms. Hallucinations were more common in DLB and PDD, whereas behavioral disturbances were frequent in FTD and DLB. Core symptoms of DLB were also present in patients diagnosed with other conditions, although cognitive fluctuations were not registered. Conclusions: DLB is likely underdiagnosed in this setting. Improved recognition and management are essential.
- 8 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (2) , 442-451
Open AccessLow Frequency of Dementia with Lewy Bodies Diagnosis in a Colombian Memory Clinic
Background: The global burden of dementia is increasing, particularly in low‐ and middle‐income countries. Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia but remains underreported and frequently misdiagnosed. Its prevalence in Latin America is largely unknown. Objective: The aim was to determine the frequency of DLB in a large memory clinic in Colombia and compare its clinical presentation with other neurodegenerative conditions, including Alzheimer's disease, frontotemporal dementia (FTD), vascular dementia, and Parkinson's disease dementia (PDD). Methods: We conducted a retrospective study at a referral memory clinic in Bogotá, Colombia, from January 2018 to December 2022. DLB was identified based on the Fourth Consensus Report criteria. Random samples of patients with other neurodegenerative conditions were selected for comparison, maintaining a maximum ratio of 4:1. Clinical assessments were conducted by an interdisciplinary team using validated neurocognitive, neuropsychiatric, neuropsychological, and functional tools. Imaging and biofluid biomarkers were not available. Results: Of 5518 patients, 38 (0.6%) were diagnosed with DLB. These individuals were predominantly male, with an average age of 72.3 years. Significant differences were observed between groups in age of onset, motor and cognitive function, and neuropsychiatric symptoms. Hallucinations were more common in DLB and PDD, whereas behavioral disturbances were frequent in FTD and DLB. Core symptoms of DLB were also present in patients diagnosed with other conditions, although cognitive fluctuations were not registered. Conclusions: DLB is likely underdiagnosed in this setting. Improved recognition and management are essential.
- Open Access
- 9 August 2025
- Published by Elsevier in The Journal of Aging Research & Lifestyle
- Vol. 14, 100023
Temporal muscle thickness predicts change in nutritional markers in individuals at risk of dementia: Insights from a 24-week longitudinal study
- 9 August 2025
- Published by Elsevier in The Journal of Aging Research & Lifestyle
- Vol. 14, 100023
Open AccessTemporal muscle thickness predicts change in nutritional markers in individuals at risk of dementia: Insights from a 24-week longitudinal study
- Open Access
- 21 April 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1053-1065
Lewy Body Dementia Research in Latin America: A Scoping Review
Background: Dementia research in Latin America (LA) has primarily focused on Alzheimer's Disease and Frontotemporal Dementia, while Lewy body dementia (LBD) has been largely forgotten.Objective: We aimed to review the available evidence on LBD in LA, offering a comprehensive perspective for understanding the lack of reports and the unique challenges and characteristics of this region.Methods: We carried out a scoping review in databases: PubMed, EMBASE, LILACS, and Web of Science. Original studies that included participants with LBD were analyzed.Results: Of the 1388 studies identified, 70 met the inclusion criteria for this review. Among them, 63 were cross‐sectional studies, three were cohort studies, two followed a case–control methodology, and only two were non‐randomized clinical trials. These studies primarily examined clinical manifestations, risk factors, neuropsychiatric and non‐motor symptoms, as well as cognitive impairment and its assessment in LBD within LA. Regarding geographical distribution, 52 studies were conducted in Brazil, seven in Argentina, the rest in Peru, Mexico, Colombia, Cuba, and Chile.Conclusions: LBD research in LA is underrepresented, with most studies being cross‐sectional, few utilizing a longitudinal design, and only two clinical trials, both of which lack rigorous methodology. Challenges include weak study designs, high heterogeneity, limited trials, and unclear differentiation within the LBD spectrum. Addressing these gaps requires increasing awareness, strengthening research capacity, securing funding, and fostering international collaboration.
- 21 April 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1053-1065
Open AccessLewy Body Dementia Research in Latin America: A Scoping Review
Background: Dementia research in Latin America (LA) has primarily focused on Alzheimer's Disease and Frontotemporal Dementia, while Lewy body dementia (LBD) has been largely forgotten.Objective: We aimed to review the available evidence on LBD in LA, offering a comprehensive perspective for understanding the lack of reports and the unique challenges and characteristics of this region.Methods: We carried out a scoping review in databases: PubMed, EMBASE, LILACS, and Web of Science. Original studies that included participants with LBD were analyzed.Results: Of the 1388 studies identified, 70 met the inclusion criteria for this review. Among them, 63 were cross‐sectional studies, three were cohort studies, two followed a case–control methodology, and only two were non‐randomized clinical trials. These studies primarily examined clinical manifestations, risk factors, neuropsychiatric and non‐motor symptoms, as well as cognitive impairment and its assessment in LBD within LA. Regarding geographical distribution, 52 studies were conducted in Brazil, seven in Argentina, the rest in Peru, Mexico, Colombia, Cuba, and Chile.Conclusions: LBD research in LA is underrepresented, with most studies being cross‐sectional, few utilizing a longitudinal design, and only two clinical trials, both of which lack rigorous methodology. Challenges include weak study designs, high heterogeneity, limited trials, and unclear differentiation within the LBD spectrum. Addressing these gaps requires increasing awareness, strengthening research capacity, securing funding, and fostering international collaboration.
- Open Access
- 1 January 2025
- Published by Universidad de Antioquia in IATREIA
- Vol. 38 (2) , 80-94
Biomarcadores no convencionales en demencia a través del examen neurológico: una revisión de la literatura
Introducción: los biomarcadores en sangre y líquido cefalorraquídeo han tomado fuerza para el diagnóstico de demencia, pero no siempre están disponibles. Objetivos: describir los biomarcadores no convencionales durante el examen neurológico. Métodos: revisión narrativa, realizando búsqueda sobre deterioro cognitivo en relación con biomarcadores no convencionales en las bases de datos PubMed, EMBASE y SciELO, incluyendo estudios originales y secundarios que describieran esta relación, además de las herramientas para su evaluación en la clínica. Resultados: los síntomas neuropsiquiátricos son una de las primeras manifestaciones y un marcador de progresión que está presente en aproximadamente el 97% de los pacientes. Depresión, ansiedad y apatía son tres posibles, evaluables con base en experticia clínica, escalas o nuevas tecnologías. Otros marcadores son bradipsiquia y alteración en la función ejecutiva, la cual afecta en un 8-13% los parámetros de función motora. Con relación a los pares craneales, puede haber alteraciones en nervio óptico y retina, cambios en los movimientos oculares e hipoacusia. El examen motor es uno de los más prometedores con la doble tarea, velocidad de la marcha y fuerza de agarre. Se ha estimado que puede influenciar más de un 50% la ocurrencia de demencia. También pueden verse alteraciones sensitivas respecto a la percepción del dolor. Por último, la aparición de dos o más reflejos de liberación frontal es un marcador de deterioro cognitivo. Conclusiones: se encontró evidencia que soporta el uso de biomarcadores no convencionales, los cuales pueden ser una alternativa para detectar tempranamente deterioro cognitivo.
- 1 January 2025
- Published by Universidad de Antioquia in IATREIA
- Vol. 38 (2) , 80-94
Open AccessBiomarcadores no convencionales en demencia a través del examen neurológico: una revisión de la literatura
Introducción: los biomarcadores en sangre y líquido cefalorraquídeo han tomado fuerza para el diagnóstico de demencia, pero no siempre están disponibles. Objetivos: describir los biomarcadores no convencionales durante el examen neurológico. Métodos: revisión narrativa, realizando búsqueda sobre deterioro cognitivo en relación con biomarcadores no convencionales en las bases de datos PubMed, EMBASE y SciELO, incluyendo estudios originales y secundarios que describieran esta relación, además de las herramientas para su evaluación en la clínica. Resultados: los síntomas neuropsiquiátricos son una de las primeras manifestaciones y un marcador de progresión que está presente en aproximadamente el 97% de los pacientes. Depresión, ansiedad y apatía son tres posibles, evaluables con base en experticia clínica, escalas o nuevas tecnologías. Otros marcadores son bradipsiquia y alteración en la función ejecutiva, la cual afecta en un 8-13% los parámetros de función motora. Con relación a los pares craneales, puede haber alteraciones en nervio óptico y retina, cambios en los movimientos oculares e hipoacusia. El examen motor es uno de los más prometedores con la doble tarea, velocidad de la marcha y fuerza de agarre. Se ha estimado que puede influenciar más de un 50% la ocurrencia de demencia. También pueden verse alteraciones sensitivas respecto a la percepción del dolor. Por último, la aparición de dos o más reflejos de liberación frontal es un marcador de deterioro cognitivo. Conclusiones: se encontró evidencia que soporta el uso de biomarcadores no convencionales, los cuales pueden ser una alternativa para detectar tempranamente deterioro cognitivo.
- 6 December 2024
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (12) , e70029
Using Routinely Collected Health Data to Estimate the Prevalence of Alzheimer's Disease and Potentially Modifiable Risk Factors in Colombia
Objective: With an increasing prevalence, Alzheimer's Disease (AD) is the most common cause of dementia. However, a percentage of potentially modifiable cases have been reported. This article describes the prevalence of four of these potentially modifiable risk factors: hearing loss, diabetes mellitus (DM), obesity, and hypertension.Methods: Descriptive cross‐sectional study with data from 2018 to 2022, using the Colombian health system database SISPRO. The population of this study consisted of all people within the age range 50–100 with a main diagnosis of AD according to the ICD‐10 codes. Subjects were divided by decades, and the prevalence ratio (PR) for the outcome of AD and each of its potentially modifiable risk factors was then calculated and adjusted by age using the Mantel‐Haenszel formula.Results: 167,556 cases of AD were identified, with 66.4% being females. Peak age was in octogenarians, and the five‐years period prevalence for people older than 50 was 12.6 cases/1000 people. The PRs showed a positive association for all risk factors, except obesity. Following age correction, obesity's PR value shifted to positive in males and overall population but remained negative for females. The highest post‐correction PR in the overall population was hypertension (1.44), followed by DM (1.34), hearing loss (1.31) and obesity (1.12). Notably, PRs had a greater magnitude in younger and male age groups.Conclusion: The results of this study are consistent with the fact that the prevalence of potentially modifiable risk factors is higher within the group of people with AD as their main diagnosis.
- 6 December 2024
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (12) , e70029
Using Routinely Collected Health Data to Estimate the Prevalence of Alzheimer's Disease and Potentially Modifiable Risk Factors in Colombia
Objective: With an increasing prevalence, Alzheimer's Disease (AD) is the most common cause of dementia. However, a percentage of potentially modifiable cases have been reported. This article describes the prevalence of four of these potentially modifiable risk factors: hearing loss, diabetes mellitus (DM), obesity, and hypertension.Methods: Descriptive cross‐sectional study with data from 2018 to 2022, using the Colombian health system database SISPRO. The population of this study consisted of all people within the age range 50–100 with a main diagnosis of AD according to the ICD‐10 codes. Subjects were divided by decades, and the prevalence ratio (PR) for the outcome of AD and each of its potentially modifiable risk factors was then calculated and adjusted by age using the Mantel‐Haenszel formula.Results: 167,556 cases of AD were identified, with 66.4% being females. Peak age was in octogenarians, and the five‐years period prevalence for people older than 50 was 12.6 cases/1000 people. The PRs showed a positive association for all risk factors, except obesity. Following age correction, obesity's PR value shifted to positive in males and overall population but remained negative for females. The highest post‐correction PR in the overall population was hypertension (1.44), followed by DM (1.34), hearing loss (1.31) and obesity (1.12). Notably, PRs had a greater magnitude in younger and male age groups.Conclusion: The results of this study are consistent with the fact that the prevalence of potentially modifiable risk factors is higher within the group of people with AD as their main diagnosis.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S6)
LBD around the world – The Latin American experience
Up to date, there are no precise reports of the prevalence of dementia with Lewy bodies (DLB) in Latin America. This can be explained by the lack of research studies and general little awareness about the disease. Notably, collaborative clinical studies are lacking, and DLB patients remain underrepresented despite their significant morbidity.The few studies investigating DLB in Latin America have been based on small samples, resulting in disparities across the region. Challenges include variability in follow‐up regimens and protocols, prompting the need for harmonization to assess the practical benefits for patients. Future efforts should prioritize collaborative initiatives and address knowledge gaps to enhance the understanding and management of DLB in Latin America.Here, we describe the first multi‐center initiative for the study of DLB in Colombia.The main objectives of this initiative are: 1) to identify the level of DLB awareness in memory clinics in Colombia, 2) to analyze the use of clinical instruments and biomarkers for DLB, 3) to characterize the Colombian DLB population, and 4) to explore the potential usefulness of biomarkers in combination with other clinical features to improve diagnostic accuracy and prognostic prediction, especially during the early stages of the disease.This initiative is linked to the European DLB consortium (E‐DLB) using harmonized procedures and protocols, allowing the opportunity to directly compare clinical and biomarker features across continents.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S6)
Open AccessLBD around the world – The Latin American experience
Up to date, there are no precise reports of the prevalence of dementia with Lewy bodies (DLB) in Latin America. This can be explained by the lack of research studies and general little awareness about the disease. Notably, collaborative clinical studies are lacking, and DLB patients remain underrepresented despite their significant morbidity.The few studies investigating DLB in Latin America have been based on small samples, resulting in disparities across the region. Challenges include variability in follow‐up regimens and protocols, prompting the need for harmonization to assess the practical benefits for patients. Future efforts should prioritize collaborative initiatives and address knowledge gaps to enhance the understanding and management of DLB in Latin America.Here, we describe the first multi‐center initiative for the study of DLB in Colombia.The main objectives of this initiative are: 1) to identify the level of DLB awareness in memory clinics in Colombia, 2) to analyze the use of clinical instruments and biomarkers for DLB, 3) to characterize the Colombian DLB population, and 4) to explore the potential usefulness of biomarkers in combination with other clinical features to improve diagnostic accuracy and prognostic prediction, especially during the early stages of the disease.This initiative is linked to the European DLB consortium (E‐DLB) using harmonized procedures and protocols, allowing the opportunity to directly compare clinical and biomarker features across continents.
- Open Access
- 24 May 2024
- Published by Elsevier in Archives of Medical Research
- Vol. 55 (4) , 103003
Assessing Neutrophil-to-Lymphocyte Ratio as a Nutritional Indicator in Community-Dwelling Older Adults
- 24 May 2024
- Published by Elsevier in Archives of Medical Research
- Vol. 55 (4) , 103003
Open AccessAssessing Neutrophil-to-Lymphocyte Ratio as a Nutritional Indicator in Community-Dwelling Older Adults
- Open Access
Nutrient Intake and Its Association with Appendicular Total Lean Mass and Muscle Function and Strength in Older Adults: A Population-Based Study
Treatment options for sarcopenia are currently limited, and primarily rely on two main therapeutic approaches: resistance-based physical activity and dietary interventions. However, details about specific nutrients in the diet or supplementation are unclear. We aim to investigate the relationship between nutrient intake and lean mass, function, and strength. Data were derived from the Gothenburg H70 birth cohort study in Sweden, including 719,70-year-olds born in 1944 (54.1% females). For independent variables, the diet history method (face-to-face interviews) was used to estimate habitual food intake during the preceding three months. Dependent variables were gait speed (muscle performance), hand grip strength (muscle strength), and the appendicular lean soft tissue index (ALSTI). Linear regression analyses were performed to analyze the relationship between the dependent variables and each of the covariates. Several nutrients were positively associated with ALSTI, such as polyunsaturated fatty acids (DHA, EPA), selenium, zinc, riboflavin, niacin equivalent, vitamin B12, vitamin D, iron, and protein. After correction for multiple comparisons, there were no remaining correlations with handgrip and gait speed. Findings of positive correlations for some nutrients with lean mass suggest a role for these nutrients in maintaining muscle volume. These results can be used to inform clinical trials to expand the preventive strategies and treatment options for individuals at risk of muscle loss and sarcopenia.
Open AccessNutrient Intake and Its Association with Appendicular Total Lean Mass and Muscle Function and Strength in Older Adults: A Population-Based Study
Treatment options for sarcopenia are currently limited, and primarily rely on two main therapeutic approaches: resistance-based physical activity and dietary interventions. However, details about specific nutrients in the diet or supplementation are unclear. We aim to investigate the relationship between nutrient intake and lean mass, function, and strength. Data were derived from the Gothenburg H70 birth cohort study in Sweden, including 719,70-year-olds born in 1944 (54.1% females). For independent variables, the diet history method (face-to-face interviews) was used to estimate habitual food intake during the preceding three months. Dependent variables were gait speed (muscle performance), hand grip strength (muscle strength), and the appendicular lean soft tissue index (ALSTI). Linear regression analyses were performed to analyze the relationship between the dependent variables and each of the covariates. Several nutrients were positively associated with ALSTI, such as polyunsaturated fatty acids (DHA, EPA), selenium, zinc, riboflavin, niacin equivalent, vitamin B12, vitamin D, iron, and protein. After correction for multiple comparisons, there were no remaining correlations with handgrip and gait speed. Findings of positive correlations for some nutrients with lean mass suggest a role for these nutrients in maintaining muscle volume. These results can be used to inform clinical trials to expand the preventive strategies and treatment options for individuals at risk of muscle loss and sarcopenia.